A Phase Ia, Randomized, Placebo-controlled, Double-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in IGRA-negative, BCG naïve Subjects
Latest Information Update: 06 Mar 2025
At a glance
- Drugs BNT 164 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; First in man
- Sponsors BioNTech
Most Recent Events
- 24 Oct 2024 Planned End Date changed from 1 Sep 2025 to 1 Jan 2026.
- 24 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Jun 2025.
- 11 Jul 2024 Status changed from recruiting to active, no longer recruiting.